Study of lifileucel for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests an experimental cell therapy called lifileucel, made from your own immune cells, for advanced endometrial cancer that has progressed after standard treatments. It aims to shrink tumors and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced endometrial cancer (any type except uterine sarcoma).
- You have tried 1 to 4 prior cancer treatments, including platinum chemotherapy and immunotherapy (like Keytruda).
- Your tumor has grown during or after your last treatment, or you stopped it due to side effects.
- You have at least one tumor that can be surgically removed to make the cell therapy.
- You are well enough to be up and active (ECOG score 0 or 1) and have a life expectancy over 6 months.
- You are not pregnant and agree to use effective birth control for up to 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
This trial tests a new combination treatment, IOV-3001 and lifileucel, for people with advanced melanoma that has not responded to standard immunotherapy and cannot be surgically removed. It aims to see if this cellular therapy is safe and effective.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.